Overview
- HSBC raised AbbVie to Buy on December 10 and increased its price target to $265, citing strengthening fundamentals.
- Skyrizi sales rose to about $4.7 billion in Q3 2025, up roughly 47% year over year, while Rinvoq reached about $2.18 billion, up about 35%.
- AbbVie guides for approximately $20 billion in Skyrizi revenue and $11 billion for Rinvoq by 2027, framing a combined ~$31 billion goal.
- The board lifted the quarterly dividend 5.5% to $1.73 on October 31, bringing the annual payout to $6.92 and extending a decades‑long growth streak.
- Shares are up about 25% year to date, outpacing the S&P 500, as investors re-rate the company’s immunology-driven growth story.